Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Change From Baseline in Fasting Plasma Glucose at Week 18

Change from baseline reflects the Week 18 FPG minus the Week 0 FPG. Means are adjusted for baseline FPG and previous anti-diabetic medication.

Time frame: Baseline, week 18

Percentage of Patients With Absolute Efficacy Response (HbA1c < 7%) at Week 18

An absolute efficacy response is defined as HbA1c \< 7.0% at 18 weeks. A non-response is defined as HbA1c \>= 7.0% at 18 weeks.

Time frame: week 18

Percentage of Patients With Absolute Efficacy Response (HbA1c < 6.5%) at Week 18

An absolute efficacy response is defined as HbA1c \< 6.5% at 18 weeks. A non-response is defined as HbA1c \>= 6.5% at 18 weeks.

Time frame: week 18

Percentage of Patients With HbA1c Lowering by at Least 0.5% From Baseline at Week 18

An efficacy response is defined as HbA1c lowered by 0.5% or more at 18 weeks. A non-response is defined as HbA1c not lowered by 0.5% or more at 18 weeks.

Time frame: Baseline, week 18

Mixed Model Repeated Measurements Analysis of Change From Baseline in HbA1c at Week 6

HbA1c is measured as a percent. The change from baseline reflects the Week 6 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c and previous anti-diabetic medication.